<DOC>
	<DOCNO>NCT00047190</DOCNO>
	<brief_summary>Phase II trial study effectiveness tipifarnib treat patient myelofibrosis myeloid metaplasia . Tipifarnib may stop growth tumor cell block enzymes necessary tumor cell growth .</brief_summary>
	<brief_title>Tipifarnib Treating Patients With Myelofibrosis Myeloid Metaplasia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate response rate MMM patient treat R115777 . II . To evaluate toxicity R115777 patient MMM . SECONDARY OBJECTIVES : I . To evaluate benefit therapy R115777 alleviate disease-associated anemia patient MMM . II . To evaluate benefit R115777 reduce palpable splenomegaly patient MMM . III . To evaluate effect R115777 hypercatabolic symptom MMM . IV . To evaluate effect R115777 pathologic increase circulate myeloid progenitor MMM patient baseline measurement measurement first cycle . V. To correlate response/relapse vitro myeloid colony sensitivity R115777 time either response relapse . VI . To evaluate effect R115777 bone marrow histologic feature MMM include osteosclerosis , reticulin fibrosis , angiogenesis ( serial bone marrow microvessel density grade ) . OUTLINE : This multicenter study . Patients receive oral tipifarnib twice daily day 1-21 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients follow every 3 month disease progression every 6 month 2 year . PROJECTED ACCRUAL : A total 18-35 patient accrue study within 15 month .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Metaplasia</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>Histopathologic confirmation ( bone marrow trephine aspirate ) myelofibrosis myeloid metaplasia pathologist/hematologist register institution ; include diagnosis MMM AMM ( agnogenic myeloid metaplasia ) , PPMM ( postpolycythemic myeloid metaplasia ) , PTMM ( postthrombocythemic myeloid metaplasia ) ; bone marrow show presence reticulin fibrosis , peripheral blood smear show presence leukoerythroblastosis dacrocytosis Bone marrow show evidence condition associate myelofibrosis , metastatic carcinoma , lymphoma , myelodysplasia , hairy cell leukemia , mast cell disease , acute leukemia ( include M7 type ) , acute myelofibrosis Bone marrow chromosome analysis peripheral blood bone marrow Fluorescent In Situ Hybridization ( FISH ) show absence chromosomal translocation ( 9:22 ) ; prior demonstration sufficient enrollment purpose At least one following : Anemia evidence hemoglobin &lt; 10 g/dL Palpable hepatosplenomegaly ANC ≥ 750/mm^3 PLT ≥ 100,000/mm^3 Total bilirubin ( direct total elevate ) ≤ UNL Alkaline phosphatase = &lt; 3 x UNL ( unless felt secondary disease ) AST ≤ 2.5 x UNL Creatinine = &lt; 1.5 x UNL Ability understand willingness sign write informed consent document Willingness follow schedule return register P2C institution ( monthly ) receive protocol treatment ECOG performance status 0 , 1 , 2 Any follow regimen may harmful develop fetus nursing child : Pregnant woman Breastfeeding woman Men woman childbearing potential sexual partner unwilling employ adequate contraception ( condom , diaphragm , birth control pill , injection , intrauterine device [ IUD ] , surgical sterilization , subcutaneous implant , abstinence , etc . ) NOTE : The effect agent ( ) develop human fetus recommend therapeutic dose unknown Use cytotoxic chemotherapy myelosuppressive agent within = &lt; 2 week prior study entry Uncontrolled intercurrent illness comorbid condition would limit compliance study requirement use R115777 felt potentially harmful ; condition include , limited : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia , Psychiatric illness/social situation Other concurrent therapy direct disease ( include Thalidomide ) use erythropoietin enrol study ; agent must discontinue time prior study entry Known quinolone sensitivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>